Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02179)

APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders

SOMERLEY CAPITAL LIMITED

Reference is made to the announcement of Jiangsu Recbio Technology Co., Ltd. (the "**Company**") dated 18 November 2026 (the "**Announcement**") in relation to, among others, the Subscription and the Whitewash Waiver. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that Somerley Capital Limited (a licensed corporation under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) to carry out Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities) has been appointed as the independent financial adviser (the "**Independent Financial Adviser**") to advise (a) the Listing Rules Independent Board Committee and the Independent Shareholders in respect of the Subscription and the Specific Mandate, and as to voting therefor; and (b) the Code Independent Board Committee and the Independent Shareholders in respect of the Subscription and the Whitewash Waiver, and as to voting therefor. Pursuant to Rule 2.1 of the Takeovers Code, the appointment of Somerley Capital Limited as the Independent Financial Adviser has been approved by the Code Independent Board Committee.

The letter from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders, containing its advice in respect of the Subscription, the Specific Mandate and the Whitewash Waiver, will be included in the circular to be despatched by the Company to the Shareholders in due course.

The Whitewash Waiver may or may not be granted by the Executive. The Whitewash Waiver, if granted, will be subject to, among other things, approval in respect of the Whitewash Waiver by at least 75% of the votes of the Independent Shareholders and in respect of the Subscription by more than 50% of the votes of the Independent Shareholders, in each case cast either in person or by proxy at the EGM. Completion is conditional upon, among other things, the Whitewash Waiver being granted by the Executive and approved by the Independent Shareholders.

Shareholders and potential investors are reminded to exercise caution when dealing in the Shares, and are recommended to consult their stockbroker, bank manager, solicitor or other professional adviser if they are in any doubt about their position and as to actions they should take.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, 24 November 2026

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the chairman of the Board and a non-executive Director, Dr. LIU Yong and Ms. WANG Jing as executive Directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive Directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.